Recoly http://www.recoly.com Enhanced Therapeutics Mon, 24 Aug 2009 10:58:34 +0000 http://wordpress.org/?v=2.7.1 en hourly 1 Recoly NV to present at UBS Global Healthcare Conference http://www.recoly.com/2009/08/24/recoly-nv-to-present-at-ubs-global-healthcare-conference/ http://www.recoly.com/2009/08/24/recoly-nv-to-present-at-ubs-global-healthcare-conference/#comments Mon, 24 Aug 2009 10:58:34 +0000 admin http://www.recoly.com/?p=206 Mr. Robert Taub, CEO, and Dr. Moshe Baru, CSO & COO, will be presenting Recoly NV at the UBS Global Healthcare Conference. The presentation will be given at 1:30 p.m. on Wednesday, September 23, 2009 at the Grand Hyatt New York in New York City.

]]> http://www.recoly.com/2009/08/24/recoly-nv-to-present-at-ubs-global-healthcare-conference/feed/ Recoly completed a phase I/II clinical trial with LongSeven http://www.recoly.com/2009/07/20/recoly-completed-a-phase-iii-clinical-trial-with-longseven/ http://www.recoly.com/2009/07/20/recoly-completed-a-phase-iii-clinical-trial-with-longseven/#comments Mon, 20 Jul 2009 13:02:19 +0000 admin http://www.recoly.com/?p=202 Recoly presented results of a phase I/II clinical trial with LongSeven during the XXII Congress of the International Society on Thrombosis and Hemostasis (ISTH) held in Boston, MA, USA. The open label, cross-over trial was conducted at the hemophilia center of the Russian Academy of Medical Sciences, Moscow, Russia. It included six hemophilia A patients with inhibitors to factor VIII. The trial evaluated the efficacy and safety of factor VIIa (FVIIa) formulated with PEGylated liposomes as compared to standard FVIIa (90µg FVIIa/kg in both treatment arms). The results indicate that formulation of FVIIa with PEGylated liposomes significantly enhances the hemostatic efficacy of FVIIa. Safety analysis indicated that the increased efficacy of liposomal FVIIa was not accompanied by increased thrombotic risk. The results suggest that in treatment of bleeding episodes in hemophilia patients with inhibitors, one dose of LongSeven is roughly equivalent to two doses of standard FVIIa given two hours apart.

]]> http://www.recoly.com/2009/07/20/recoly-completed-a-phase-iii-clinical-trial-with-longseven/feed/ In-licensing of Rec-200 IP http://www.recoly.com/2008/12/24/in-licensing-of-rec-200-ip/ http://www.recoly.com/2008/12/24/in-licensing-of-rec-200-ip/#comments Wed, 24 Dec 2008 14:26:56 +0000 admin http://www.recoly.com/?p=61 Licensing Agreement with Innovative Drug Delivery Ltd. (”IDD”) for the In-Licensing of liposomal glucocorticoid IP Rights.

Recoly has entered a perpetual license agreement with IDD, a company related to the Hebrew University, Jerusalem, Israel, for the in-licensing by Recoly of certain IP related to the encapsulation of glucocorticoids in liposomes. Results related to the technology were published in the January 2008 ARTHRITIS & RHEUMATISM magazine.

]]> http://www.recoly.com/2008/12/24/in-licensing-of-rec-200-ip/feed/ LongSeven http://www.recoly.com/2008/12/15/longseven/ http://www.recoly.com/2008/12/15/longseven/#comments Mon, 15 Dec 2008 10:40:13 +0000 admin http://www.recoly.com/?p=1 Recoly commenced today a phase I/II clinical trial with LongSeven. Study results are expected in 2Q/2009. The clinical trial with 6 patients is a single center, open label control, comparative randomized phase I/II study.

]]> http://www.recoly.com/2008/12/15/longseven/feed/